Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1635-1642

  Kim, Jae Sik ^a   Lee, Sang Don ^b   Lee, Sang Jin ^c   Chung, Moon Kee ^b  

^a The Catholic University of Korea   (South Korea)

^b Pusan National University Yangsan Hospital   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Adenovirus; Hormone independent; Prostate cancer; Suicide gene

Indexed keywords

E1A PROTEIN; ONCOLYTIC ADENOVIRUS; THYMIDINE KINASE; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; E1A GENE; E4 GENE; FLOW CYTOMETRY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROTEIN FOLDING; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

EID: 84888177734     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S51749     Document Type: Article

References (27)

1. Annual report of cancer statistics in Korea in 2008. Ministry of Health and Welfare. 2010:19-31.
2. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005;65:7194-7204.
3. Lee SJ, Kim HS, Yu R, et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther. 2002;6:415-421.
4. Graham FL. Growth of 293 cells in suspension culture. J Gen Virol. 1987;68 Pt 3:937-940.
5. Li X, Zhang YP, Kim HS, et al. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res. 2005;65:1941-1951.
6. Kasono K, Blackwell JL, Douglas JT, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res. 1999;5:2571-2579.
7. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 2000;60:5031-5036.
8. Gardner TA, Sloan J, Raikwar SP, Kao C. Prostate cancer gene therapy: past experiences and future promise. Cancer Metastasis Rev. 2002;21:137-145.
9. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. 2005;8:61-74.
10. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004;6:611-623.
11. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-1733.
12. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
13. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
14. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A. 1997;94:3352-3356.
15. Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001;61:2953-2960.
16. Li D, Duan L, Freimuth P, O'Malley BW Jr. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res. 1999;5:4175-4181.
17. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999;59:325-330.
18. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003;14:227-241.
19. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002;62:3812-3818.
20. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9:1408-1412.
21. Johanson TJ, Höti N, Liu C, et al. Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer. Cancer Gene Ther. 2013;20:394-402.
22. Zhang Z, Zhang X, Newman K, Liu X. MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol Cancer Ther. 2012;11:2410-2418.
23. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953-1962.
24. Parajuli P, Mosley RL, Pisarev V, et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol. 2001;29: 1185-1193.
25. Masten BJ, Olson GK, Kusewitt DF, Lipscomb MF. Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol. 2004;172:4077-4408.
26. McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95:3489-3497.
27. Shurin GV, Chatta GS, Tourkova IL, Zorina TD, Esche C, Shurin MR. Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Exp Gerontol. 2004;39:339-348.